ENDOCUFF VISION® increased the adenoma detection rate(ADR) in a large multicentre, randomised controlled trial2
*Some studies were conducted using ENDOCUFF™, an earlier version of the current device, ENDOCUFF VISION®
Many lesions are located in blind areas
One cause of missed lesions is incomplete visualisation of the entire colon5
Most missed lesions are located behind folds, out of view of standard colonoscopy1
The adenoma and polyp miss rates with standard colonoscopy have been reported to be 24% and 41%, respectively8,9
ENDOCUFF VISION® can reduce your adenoma miss rate
ENDOCUFF VISION® reduced the adenoma miss rate by over 20% compared to standard colonoscopy (p<0.001)*2
The adenoma miss rate in the proximal colon was just 10.4% with ENDOCUFF VISION® (p=0.002)*2
Adapted from Triantafyllou K, et al. 20172
*This study was conducted using ENDOCUFF™ an earlier version of the current device, ENDOCUFF VISION®
ENDOCUFF VISION® can increase your ADR to decrease the risk of CRC
Every 1% increase in ADR is associated with a 3% decrease in the risk of interval CRC, and 5% decrease in the risk of fatal CRC6
Endoscopists who increased their ADR during screening colonoscopies significantly reduced the risk of their patients developing interval and fatal CRC (p=0.006 and p=0.035, respectively)7
Several studies have found that ENDOCUFF VISION® significantly increases ADRs*3-5
BCSP: Bowel Cancer Screening Programme.
*Some studies were conducted using ENDOCUFF™ an earlier version of the current device, ENDOCUFF VISION®
- Pickhardt PJ, et al. Ann Intern Med 2004; 141(5): 352-359.
- Triantafyllou K, et al. Endoscopy 2017 doi: 10.1055/s-0043-114412.
- Tsiamoulos ZP, et al. Gastrointest Endosc 2017 doi: 10.1016/j.gie.2017.04.001.
- Ngu WS, et al. UEG Journal 2016; 4(6): 808-809.
- De Palma GD, et al. Gastrointest Endosc 2017 doi: 10.1016/j.gie.2016.12.027.
- Corley DA, et al. N Engl J Med 2014; 370(14): 1298-1306.
- Kaminski MF, et al. Gastroenterology 2017; 153(1): 98-105.
- Rex DK, et al. Gastroenterology 1997; 112(1): 24-28.
- Gralnek IM, et al. Lancet Oncol 2014; 15(3): 353-360.